SVB Securities analyst Roanna Ruiz reiterated a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) on June 7 and set a price target of $21.00. The company’s shares closed yesterday at $11.66.
According to TipRanks, Ruiz is an analyst with an average return of -8.2% and a 46.84% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Lantheus, ARS Pharmaceuticals, and scPharmaceuticals.
Currently, the analyst consensus on NewAmsterdam Pharma Company is a Moderate Buy with an average price target of $21.50.
See the top stocks recommended by analysts >>
NAMS market cap is currently $953.4M and has a P/E ratio of -56.88.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Frazier Lifesciences Acquisition Corp is a blank check company.
Read More on NAMS:
- NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
- NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares
- NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
- NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
- NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
